Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for alks
-0.48 (-0.65%)
After Hours: 72.88 0.00 (0.00%)
Dec 1, 4:17PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 71.29 - 74.31
52 week 52.29 - 75.99
Open 73.46
Vol / Avg. 692,624.00/856,387.00
Mkt cap 11.37B
P/E     -
Div/yield     -
EPS -0.85
Shares 150.06M
Beta 1.53
Inst. own 100%
Nov 18, 2015
Alkermes Plc at Jefferies Autumn Global Healthcare Conference - Webcast
Nov 10, 2015
Alkermes Plc at Credit Suisse Healthcare Conference
Oct 29, 2015
Q3 2015 Alkermes Plc Earnings Release
Oct 29, 2015
Q3 2015 Alkermes Plc Earnings Call - Webcast
Oct 6, 2015
Alkermes Plc to Discuss FDA Approval of ARISTADAT for Treatment of Schizophrenia - Webcast
Sep 17, 2015
Alkermes Plc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -53.07% -4.86%
Operating margin -50.71% -14.08%
EBITD margin - 1.77%
Return on average assets -17.12% -1.72%
Return on average equity -23.50% -2.44%
Employees 1,300 -
CDP Score - -


Connaught House 1 Burlington Road, Dublin 4
DUBLIN, 00000
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Company's main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane M. Cooke President
Age: 52
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon G. Pugh Chief Operating Officer, Senior Vice President, Chief Risk Officer
Age: 57
Bio & Compensation  - Reuters
Elliot W. Ehrich M.D. Executive Vice President, Research and Development and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Kathryn L. Biberstein Senior Vice President, Chief Legal Officer and Chief Compliance Office, Secretary
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rebecca J. Peterson Senior Vice President - Corporate Communications
Age: 39
Bio & Compensation  - Reuters